Investors

Welcome to our Investor Centre

Please click on the Profiles below to see more details on our other clients:

All of the information contained within this website has been compiled from sources believed to be reliable, but no warranty, expressed or implied, is given that the information is complete or accurate or that it is fit for a particular purpose. All such warranties are expressly disclaimed and excluded. Any opinions, recommendations and forecasts referred to are not those of Walbrook PR Limited but are expressly those of third parties, such as investment analysts and financial journalists. Such opinions, recommendations and forecasts may have been superseded and thus may not necessarily be the current opinions, recommendations and forecasts of the relevant analyst/broker. None of the content of this website should be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell, the securities of any listed Company mentioned or featured herein as it is for information only. Any recommendations referred to by third parties do not necessarily imply the suitability of particular securities for individual situations. The value of securities and the income from them may fluctuate. It should be remembered that past performance is not necessarily a guide to future performance. You are strongly advised to seek guidance from a professional investment adviser before entering into any contract to buy or sell any security featured herein. By reading this disclaimer, and ticking the box below, you confirm that you accept and understand its content, and that you shall not hold Walbrook PR Limited, its directors and staff nor any of its subsidiaries or connected companies liable for any loss that you may sustain should you decide to buy or sell any of the mentioned securities.

Verici Dx plc

Company Profile

Company website
Sector
Health Care/Medical Equipment and Services (Medical Services)
Description

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Investor Access

22 Nov
Event information

The CEO will be providing a live presentation relating to the Company’s recent global licensing and commercialisation agreement for its pre-transplant test (Clarava™) with Thermo Fisher Scientific via the Investor Meet Company platform on 22 November 2023

Investors can sign up to Investor Meet Company for free and add to meet Verici Dx plc via the following link: https://www.investormeetcompany.com/verici-dx-plc/register-investor
Venue
Online
Time
Wednesday 22 November 2023 at 5pm (GMT)
Financial Calendar
 Event Date
Year End31 December
Half  Year End30 June
Preliminary Results*June
Interim Results*September
AGM*TBC

* Months based on previous announcements of this kind